Search Results
Your search for ,had matches 18483 pages
Showing 11251 - 11300Integration of Oncology and Palliative Care in a Solid Tumor Inpatient Service
In a retrospective study reported in the Journal of Oncology Practice, Riedel et al found that integration of oncology and palliative care in a solid tumor inpatient service resulted in improvements in quality-of-care metrics during the first year of implementation. Study Details The study...
Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors
In a single-center phase II study reported in JAMA Oncology, Feng et al found that individualized adaptive stereotactic body radiotherapy achieved high rates of local tumor control with low complication rates in patients with liver tumors and preexisting liver dysfunction. Study Details The study ...
FDA Accepts sBLA, Grants Priority Review for Obinutuzumab in Previously Untreated Follicular Lymphoma
On August 28, the U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for obinutuzumab (Gazyva) in combination with chemotherapy followed by obinutuzumab alone for patients with previously untreated follicular lymphoma....
Metastasis-Free Survival as Surrogate for Overall Survival in Localized Prostate Cancer
In a meta-analysis reported in the Journal of Clinical Oncology, Xie et al found that metastasis-free survival was a strong surrogate for overall survival in patients with localized prostate cancer, potentially providing a metric that could accelerate assessment of new adjuvant therapy approaches. ...
Concurrent Treatment With OX40 Agonist Antibody and PD-1 Blockade
Although the potential for immunotherapy to improve outcomes for patients with cancer, particularly through a combination of agents targeting immune inhibitory pathways, is becoming increasingly evident, how to optimally combine the many new immunotherapy agents being developed remains a major...
HPV Vaccination Rates Especially Low Among Childhood Cancer Survivors
The rate of human papillomavirus (HPV) vaccination in the United States is increasing, but remains lower than ideal. A new study suggests that survivors of childhood cancer receive the HPV vaccine at an even lower rate than their peers without cancer—24% vs 40%, respectively. Nearly...
Palliative Care May Substantially Decrease Health-Care Utilization in Patients With Advanced Cancer
A new population-based study shows that palliative care substantially decreased health-care utilization among Medicare beneficiaries with advanced cancer, resulting in less intensive care being delivered at the end of life. This included lower rates of hospitalization, fewer invasive procedures,...
Obinutuzumab vs Rituximab Plus CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma
The phase III GOYA trial has shown no progression-free survival advantage with obinutuzumab (Gazyva) vs rituximab (Rituxan) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced diffuse large B-cell lymphoma (DLBCL). The results were...
Women More Likely Than Men to Experience Response After Induction Chemoradiotherapy and Esophagogastrectomy for Esophageal Cancer
Female patients with locally advanced esophageal cancer treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published by...
Loss of Heterozygosity in BRCA Gene May Influence Survival in Breast and Ovarian Cancers
Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2 mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance to a common...
Reduced-Dose Cabazitaxel After Docetaxel in Metastatic Castration-Resistant Prostate Cancer
In the phase III PROSELICA trial reported by Eisenberger et al in the Journal of Clinical Oncology, a cabazitaxel (Jevtana) dose of 20 mg/m2 (C20) was noninferior for overall survival vs the currently recommended dose of 25 mg/m2 (C25) after docetaxel treatment in metastatic castration-resistant...
African American Men Have Lowest Survival Rates Among Patients With Anal Cancer
Over the past 30 years, squamous cell carcinoma of the anus has been one of the few cancers with a steadily rising incidence in the United States, with the most rapid increase seen in black men. To further investigate this trend, researchers at the University of Texas Southwestern Medical Center...
Psychological Outcomes in Adolescents With a Parent Dying of Cancer
In a study in the Swedish population reported by Beernaert et al in the Journal of Clinical Oncology, distrust in the end-of-life care provided to a parent with cancer was associated with long-term adverse emotional/psychological effects among bereaved adolescents. Study Details The study...
Anti–Trop-2 Antibody-Drug Conjugate Produces Durable Responses in Metastatic Triple-Negative Breast Cancer
AS REPORTED in the Journal of Clinical Oncology by Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center and Harvard Medical School, and colleagues, the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan has been found to produce durable responses in patients with heavily...
Adjuvant Temozolomide in 1p/19q Non-Codeleted Anaplastic Glioma
Interim results of the phase III CATNON trial (EORTC study 26053-22054) indicate a survival benefit of adjuvant temozolomide in 1p/19q non-codeleted anaplastic glioma. These findings were reported in The Lancet by van den Bent et al. Study Details In the open-label 2 x 2 factorial trial, 745...
Early-Phase Study Finds Vitamin C May Activate TET2 Function
Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published by Cimmino et al in Cell....
Liquid Biopsies Identify Distinct Genomic Profiles With Potentially Targetable Alterations in Carcinoma of Unknown Primary
Next-generation sequencing of circulating tumor DNA (ctDNA) identified distinct genomic profiles with potentially targetable alterations in 99.7% of patients with carcinoma of unknown primary (CUP) who have detectable alterations, according to results published by Kato et al in Cancer Research....
Detection of Early-Stage Cancers With Circulating Tumor DNA
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center, Baltimore, reported they have developed a test that spots tiny amounts of cancer-specific DNA in blood, and have used it to accurately identify more than half of 138 people with...
Adding First-Line Selective Internal Radiotherapy to Chemotherapy in Patients With Liver Metastases From Colorectal Cancer
A meta-analysis of three randomized trials (FOXFIRE, SIRFLOX, and FOXFIRE-Global) indicates no overall survival benefit of adding first-line selective internal radiotherapy to chemotherapy in patients with liver metastases from colorectal cancer. The findings were reported by Wasan et al in The...
Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism
Because unprovoked venous thromboembolism may be the first sign of occult cancer, or cancer of an unknown primary origin, screening is often considered in patients with the condition to detect underlying cancer at an early, curable stage. However, extensive screening tests may yield false-positive...
Crizotinib in Pediatric ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors
In a Children’s Oncology Group study, high response rates were achieved with crizotinib (Xalkori) treatment in pediatric ALK-positive anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors. These results were reported by Mossé et al in the Journal of Clinical...
Off-the-Shelf, Virus-Specific T Cells for Treating Viral Infections After Transplantation
In a phase II study reported in the Journal of Clinical Oncology, Tzannou et al found that use of off-the-shelf, broad-coverage, adoptively transferred, virus-specific T cells was feasible and effective in treating viral infections in patients who had undergone allogeneic hematopoietic stem cell...
Patricia Ganz, MD, Appointed Editor-in-Chief of JNCI
ON JULY 1, Patricia Ganz, MD, assumed editorial leadership of JNCI: Journal of the National Cancer Institute. As Editor-in-Chief, she is also responsible for JNCI Monographs. Dr. Ganz is Director of Cancer Prevention & Control Research at the University of California Los Angeles (UCLA)’s...
Pursuing Combination Strategies With Checkpoint and Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma
PRIMARY LIVER CANCER is the second leading cause of cancer-related death worldwide. Hepatocellular carcinoma accounts for 90% of liver cancer, with around 800,000 new cases diagnosed globally each year.1 In contrast to the stable or declining trends observed for most neoplasms, the incidence and...
CheckMate 040: Nivolumab Is Active in Advanced Hepatocellular Carcinoma
NIVOLUMAB (OPDIVO) has been found to produce durable responses in patients with advanced hepatocellular carcinoma in the phase I/II CheckMate 040 trial. These findings were reported in The Lancet by Anthony B. El-Khoueiry, MD, of USC Norris Comprehensive Cancer Center, and colleagues.1 Currently,...
International Consensus (or Not) on Management of Advanced Prostate Cancer
ALTHOUGH THE National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) strongly influence the management of advanced prostate cancer, they do not always reflect actual clinical practice. It turns out that in the real world, there are multiple areas ...
Cutting-Edge Induction Strategies and Novel Approach to Reducing Skeletal-Related Events Explored in Multiple Myeloma
THE ADDITION of daratumumab (Darzalex) to a triplet induction regimen led to good responses in newly diagnosed multiple myeloma, but not without toxicities. And in the treatment of myeloma bone disease, denosumab (Xgeva) in place of zoledronic acid preserved renal function and may be associated...
Updates of Key Trials in Metastatic Non–Small Cell Lung Cancer: KEYNOTE-024 and AvaALL
IMMUNOTHERAPY AND ANTIANGIOGENESIS were highlighted in a session on metastatic non–small cell lung cancer (NSCLC) at the Best of ASCO New Orleans meeting. Matthew Gubens, MD, MS, presented the selected abstracts from the ASCO Annual Meeting.1 Dr. Gubens is Associate Professor of Thoracic Medical...
Fighting Misinformation in HPV-Related Cancer Prevention
FAKE NEWS, junk science, and alternative facts seem pervasive in our current culture, to the detriment of important, verified scientific advancements. One area where this is quite evident is the vaccine against human papillomavirus (HPV). Although we have had a safe, effective vaccine since 2006...
PD-L1 Expression and Radiation Resistance in Head and Neck Squamous Cell Carcinoma
According to a study by Heath D. Skinner, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues, the primary cause of death in patients with head and neck squamous cell carcinoma is local treatment failure. Although human papillomavirus (HPV)-positive head and neck squamous ...
‘Slow, Incremental Changes’ Are Increasing Participation of Older Adults in Clinical Trials
Older adults continue to be proportionally underrepresented in oncology clinical trials, but the participation rate of adults aged 65 and older is increasing by “slow, incremental changes,” Stuart M. Lichtman, MD, FACP, FASCO, noted in an interview with The ASCO Post. Prompting those changes are...
A Personal Tribute to Angela H. Brodie, PhD, a Scientist Who Transformed Breast Cancer Treatment
Angela H. Brodie, PhD, a pioneer in breast cancer research, passed away on June 7, 2017, from complications of Parkinson’s disease and pancreatic cancer. An obituary for Dr. Brodie was published previously in the June 25, 2017, issue of The ASCO Post. Here, Dr. Balkees Abderrahman shares a...
Recent FDA Actions Include New Drug Approvals in Leukemia, Expanded Approvals in Colorectal Cancer and Graft-vs-Host Disease
The U.S. Food and Drug Administration (FDA) recently granted approval, expanded approval, and breakthrough therapy designation to numerous treatments across a range of tumor types and malignancies. New Drug Approvals Daunorubicin-Cytarabine Combination (Vyxeos): On August 3, the FDA granted...
On My Way to Hospice Care, Immunotherapy Saved My Life
Two years ago, I was on my way to hospice care after numerous treatments, including surgery, chemotherapy, and radiation therapy failed to stop the progression of my stage IV castration-resistant prostate cancer. A last-minute call from my oncologist about a phase I combination trial of the...
Association of Pretransplant Vitamin D Deficiency and Relapse in Myeloid Malignancies
A German retrospective study has found that pretransplantation vitamin D deficiency is associated with an increased risk of relapse in patients undergoing allogeneic stem cell transplantation (SCT) for myeloid malignancies. These findings were reported by Radujkovic et al in the Journal of Clinical ...
Plasma Epstein-Barr Virus DNA Screening for Nasopharyngeal Cancer
In a Hong Kong study reported in The New England Journal of Medicine, Chan et al found that screening for circulating cell-free Epstein-Barr virus (EBV) DNA is useful in detecting nasopharyngeal carcinoma in asymptomatic individuals. Study Details In the study, 20,174 participants underwent...
Making Our Future Plans Happen Now
The following essay by Hope S. Rugo, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. I was in...
Unraveling the Complexities of Cellular Immunotherapy and Its Potential to Cure Some Cancers
This past fall, the Fred Hutchinson Cancer Research Center in Seattle opened an all-encompassing 9,222-square foot outpatient cellular immunotherapy clinic, specifically designed to serve patients participating in the center’s novel immunotherapy clinical trials, which mainly focus on chimeric...
Triple-Negative Breast Cancer: Practical Approach, Promising Research
Triple-negative breast cancer has a reputation for being a particularly challenging malignancy, but breast cancer specialist Nancy Davidson, MD, Senior Vice President of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, Seattle, put this in perspective in a recent...
ASCO Guideline on Stage IV NSCLC Therapy Updated
An update of the ASCO clinical practice guideline on the systemic treatment of patients with stage IV non–small cell lung cancer (NSCLC) clarifies the role of immunotherapy in this setting. The update, published by Hanna et al in the Journal of Clinical Oncology, also provides new...
Short-Term Risk of Arterial Thromboembolism in Newly Diagnosed Patients With Cancer
Patients newly diagnosed with cancer may have a substantially increased short-term risk of arterial thromboembolism, according to a study published by Navi et al in the Journal of the American College of Cardiology. Patients with cancer face an increased risk of medical complications. However, the ...
Germline Mutations in Apparent Sporadic Pancreatic Adenocarcinoma
As reported by Shindo et al in the Journal of Clinical Oncology, deleterious germline mutations in known pancreatic cancer susceptibility genes were frequently found in patients with pancreatic cancer who do not have a reported family history of cancer. Study Details The study involved sequencing ...
Surveillance Mammography by Life Expectancy in Older Breast Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Freedman et al found that many older breast cancer survivors with a limited life expectancy still undergo annual surveillance mammography despite the absence of known benefits. Study Details The study involved analysis of National Health...
Effect of Azithromycin on Airflow Decline–Free Survival After Allogeneic HSCT for Hematologic Malignancy
The French phase III ALLOZITHRO trial, stopped early due to excessive hematologic relapse in the azithromycin group, showed worse airflow decline–free survival with azithromycin vs placebo after hematopoietic stem cell transplantation (HSCT) for hematologic malignancy. The study findings were ...
Survival After In-Hospital Cardiac Arrest in Patients With Advanced Cancer
In a study reported in the Journal of Oncology Practice, Bruckel et al found that among patients with in-hospital cardiac arrest, those with advanced cancer had lower survival rates and were more frequently designated Do Not Attempt Resuscitation (DNAR) within 48 hours after return of spontaneous...
Partial-Breast and Reduced-Dose Radiotherapy After Breast-Conserving Surgery
The UK IMPORT LOW phase III trial has shown noninferiority in local relapse for partial-breast and reduced-dose vs standard whole-breast radiotherapy after breast-conserving surgery in early breast cancer. These study results were reported by Coles et al in The Lancet. Study Details In the...
Clonal Hematopoiesis in Patients With Nonhematologic Cancers
In a study of nearly 9,000 people treated for solid tumors, researchers found that radiation treatment and tobacco use were linked to higher rates of blood-based DNA mutations that could lead to a higher risk for blood cancers such as leukemia. The study, published by Coombs et al in...
Lung Cancer Clinical Trial Eligibility Criteria Increase in Number, Complexity
With the advent of molecular targeted therapies and immunotherapy, eligibility criteria have increased in number and complexity for lung cancer clinical trials, according to an analysis published by Garcia et al in the Journal of Thoracic Oncology. Despite calls to streamline cancer clinical trial...
Genomic Characteristics and Immune Infiltration in Triple-Negative Breast Cancer
In a study reported in JAMA Oncology, Karn et al found that triple-negative breast cancers with high immune gene expression levels were characterized by lower clonal heterogeneity, reduced copy number alterations, and lower somatic mutation and neoantigen loads. Study Details In the study, DNA...
Out-of-Pocket Costs Remain High, Even for Insured Patients With Cancer
One-third of insured people with cancer end up paying more out-of-pocket than they expected, despite having health insurance coverage, researchers at the Duke Cancer Institute have found. The data showed that costs such as copays and deductibles could lead to financial distress among insured...
